Compare GBIO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBIO | GNTA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | Italy |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 34.0M |
| IPO Year | 2020 | 2021 |
| Metric | GBIO | GNTA |
|---|---|---|
| Price | $5.54 | $1.49 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.88 | N/A |
| AVG Volume (30 Days) | 61.5K | ★ 122.9K |
| Earning Date | 11-05-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $1.28 |
| 52 Week High | $12.50 | $10.00 |
| Indicator | GBIO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 36.33 |
| Support Level | $5.20 | $1.28 |
| Resistance Level | $5.54 | $1.70 |
| Average True Range (ATR) | 0.24 | 0.18 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 66.67 | 24.68 |
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.